Discover the power of Jivi
EHL rFVIIIs are not the same: The difference is Jivi
1
See how Jivi can help your patients get more out of life
* Please refer to local prescribing information. Not all patients are candidates for 1x weekly dosing. In non-EU countries other FVIII treatments may have previously launched – or are currently available – which also offer 1x weekly dosing.
† Based on head-to-head studies comparing the pharmacokinetic profiles of Jivi vs. rFVIII-Fc and Jivi vs. rurioctocog alfa pegol
References
- Jivi Summary of Product Characteristics. Return to content
- Paik J and Deeks ED. Adis Drug Evaluation. Drugs 2019; 79(10): 1147-115. Return to content
- Reding MT et al. Haemophilia 2020;26:e201–e204. Return to content
- Shah A et al. Ann Hematol 2019; 98(9): 2035-2044. Return to content
- Reading MT et al. J Thromb Haemost 2017; 15: 411-419. Return to content
- Lalezari S et al. Haemophilia. 2019; 25: 1011-1019 Return to content
- Solms A, et al. Ann Hematol 2020; 99, 2689–2698 Return to content
